Nasus Pharma is trading 12.04% higher at $4.00 after announcing the first patient was enrolled and dosed in its Phase 1 NS003 study. - Announced September 29, the trial evaluates pharmacokinetics and safety of intranasal ondansetron formulation NS003. - Topline data are expected in Q4 2026; shares are up from the September 29 close of $3.57. - The release neither reported nor explicitly attributed a stock-price reaction; the milestone is the clearest explanation for the September 30 gain.